Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359 | Director | January 17, 2017 | January 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 235,036 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 235,036 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
MARINUS PHARMACEUTICALS, INC.
Report date January 17, 2017 · Filed January 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2027-01-17 | Direct | 10,500 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 10,500 · Balance 10,500 F1: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17. |
| Restricted stockSEC Table II · derivative / convertible security | Direct | 4,500 |
Reported balance
After 2017-01-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-17 · Grant · Acquired 4,500 · Balance 4,500 F2: Each share of restricted stock represents the right to receive, at settlement, one share of common stock. F3: All shares of restricted stock vest on 1/17/18. F4: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17.
F2: Each share of restricted stock represents the right to receive, at settlement, one share of common stock.
F3: All shares of restricted stock vest on 1/17/18.
F4: Not applicable.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,201 |
Reported balance
After 2020-04-08 transaction · row 1
1 source rowRow 1 · 2020-04-08 · Disposition to issuer · Disposed 9,291 · Balance 61,201 F1: The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 164,472 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2034-05-23 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-13 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 44,000 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001628280-26-048010 · wk-form4_1783973127.xml · derivative · entry 4 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2035-05-29 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 32,500 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001628280-26-048010 · wk-form4_1783973127.xml · derivative · entry 3 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2034-05-23 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 21,000 | Not disclosed Strike: $1.37 | Not disclosed |
DisclosureSEC source: 0001628280-26-048010 · wk-form4_1783973127.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2033-06-15 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerCommon Stock | 164,472 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-048010 · wk-form4_1783973127.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2 · shares: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · shares: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. F2 · price: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · price: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 63,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274301 · ownership.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,036 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:23 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 79,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039526 · wk-form4_1780345434.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,472 F1 · shares: The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001587788-26-000002 · wk-form4_1779395521.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 41,800 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001587788-26-000002 · wk-form4_1779395521.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2036-05-20 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 20, 2027. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085448 · ownership.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,555 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001628280-25-028824 · wk-form4_1748894896.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028824 · wk-form4_1748894896.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,599 F1 · shares: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000038 · wk-form4_1747861088.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000038 · wk-form4_1747861088.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076213 · ownership.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,555 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001628280-24-025210 · wk-form4_1716581657.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-025210 · wk-form4_1716581657.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,599 F1 · shares: The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000040 · wk-form4_1716411078.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 2,167 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 2,917 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001055726-24-000040 · wk-form4_1716411078.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-05-21 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 21, 2025. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000032 · wk-form4_1715893857.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000032 · wk-form4_1715893857.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039143 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,244 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001628280-23-022453 · wf-form4_168694598491957.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 5,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022453 · wf-form4_168694598491957.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,599 F1 · shares: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:53 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000036 · wk-form4_1684270397.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:53 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000036 · wk-form4_1684270397.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:53 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000036 · wk-form4_1684270397.xml · derivative · entry 4 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:53 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 35,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001055726-23-000036 · wk-form4_1684270397.xml · derivative · entry 3 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-15 F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 15, 2024. Read SEC document |
| January 15, 2023 Filed Jan 17, 2023 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000001 · wf-form4_167398949169166.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both Read SEC document |
| January 15, 2023 Filed Jan 17, 2023 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000001 · wf-form4_167398949169166.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033982 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,894 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:15 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001628280-22-015586 · wf-form4_165368251000420.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 26, 2023 and (ii) the Issuer's next annual meeting of stockholders following May 26, 2022. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 28,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001055726-22-000040 · wf-form4_165281934246034.xml · derivative · entry 4 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-16 F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Options to vest 100% on May 16, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000040 · wf-form4_165281934246034.xml · derivative · entry 3 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F3 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000040 · wf-form4_165281934246034.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000040 · wf-form4_165281934246034.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| January 15, 2022 Filed Jan 18, 2022 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000002 · wf-form4_164253996843398.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,273 Underlying: Common Stock · 4,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both Read SEC document |
| January 15, 2022 Filed Jan 18, 2022 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000002 · wf-form4_164253996843398.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:19 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038223 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,323 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:18 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 12,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-011359 · wf-form4_162223309169622.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,449 F1 · shares: The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000046 · wf-form4_162128327904320.xml · derivative · entry 4 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 14, 2021 Filed May 17, 2021 20:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000046 · wf-form4_162128327904320.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000046 · wf-form4_162128327904320.xml · derivative · entry 3 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 27,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001055726-21-000046 · wf-form4_162128327904320.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-05-13 F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 13, 2022. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 00:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000003 · wf-form4_161075662594602.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,547 Underlying: Common Stock · 4,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 00:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000003 · wf-form4_161075662594602.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| December 03, 2020 Filed Dec 3, 2020 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 10,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061502 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,557 F2 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| December 03, 2020 Filed Dec 3, 2020 21:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061502 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,727 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in three equal installments on the first three anniversaries of the date of grant. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:39 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 6,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006716 · edgar.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,073 F1 · shares: The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000034 · wf-form4_158957306492147.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock · 8,700 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 13,300 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001055726-20-000034 · wf-form4_158957306492147.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2030-05-14 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.